K. Pittman
About
K. Pittman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, K. Pittman has authored 25 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in K. Pittman's work include Colorectal Cancer Treatments and Studies (7 papers), Bone health and treatments (5 papers) and Lung Cancer Treatments and Mutations (5 papers). K. Pittman is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Bone health and treatments (5 papers) and Lung Cancer Treatments and Mutations (5 papers). K. Pittman collaborates with scholars based in Australia, United Kingdom and United States. K. Pittman's co-authors include Peter J. Selby, Jennifer Southgate, Brendan Smith, G. Eric Blair, C. Bradley, S A Burchill, Robert J. Motzer, Bernard Escudier, Thomas E. Hutson and Dongrui R. Lu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.
In The Last Decade
K. Pittman
25 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| K. Pittman Australia | 15 | 903 | 774 | 686 | 502 | 267 | 25 | 1.7k | ||
| Naoki Kanomata Japan | 22 | 840 0.9× | 549 0.7× | 528 0.8× | 337 0.7× | 151 0.6× | 104 | 1.7k | ||
| Alison M. Schram United States | 25 | 1.1k 1.2× | 1.1k 1.4× | 862 1.3× | 783 1.6× | 465 1.7× | 100 | 2.9k | ||
| Shuchi S. Pandya United States | 19 | 980 1.1× | 895 1.2× | 900 1.3× | 365 0.7× | 101 0.4× | 69 | 2.1k | ||
| Lorenza Pecciarini Italy | 17 | 860 1.0× | 836 1.1× | 356 0.5× | 349 0.7× | 173 0.6× | 42 | 2.1k | ||
| Yukishige Yamada Japan | 19 | 1.2k 1.3× | 857 1.1× | 652 1.0× | 279 0.6× | 461 1.7× | 46 | 2.3k | ||
| Sheryl K. Elkin United States | 15 | 498 0.6× | 817 1.1× | 446 0.7× | 280 0.6× | 230 0.9× | 22 | 1.5k | ||
| Laura Galluzzo Argentina | 13 | 425 0.5× | 876 1.1× | 249 0.4× | 600 1.2× | 175 0.7× | 40 | 1.6k | ||
| Pierre Rudolph Germany | 25 | 607 0.7× | 621 0.8× | 323 0.5× | 335 0.7× | 91 0.3× | 41 | 1.5k | ||
| Patricia A. Shaw Canada | 29 | 1.1k 1.2× | 976 1.3× | 259 0.4× | 623 1.2× | 406 1.5× | 57 | 3.0k | ||
| Susanna Cappia Italy | 24 | 766 0.8× | 651 0.8× | 748 1.1× | 363 0.7× | 293 1.1× | 56 | 2.0k |
Countries citing papers authored by K. Pittman
Since
Specialization
Citations
This map shows the geographic impact of K. Pittman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Pittman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Pittman more than expected).
Fields of papers citing papers by K. Pittman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by K. Pittman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Pittman. The network helps show where K. Pittman may publish in the future.
Co-authorship network of co-authors of K. Pittman
This figure shows the co-authorship network connecting the top 25 collaborators of K. Pittman. A scholar is included among the top collaborators of K. Pittman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Pittman. K. Pittman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Knox, Jennifer J., Carlos H. Barrios, T.M. Kim, et al.. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology. 28(6). 1339–1345.
2.
Pittman, K., Yoland Antill, Amanda Goldrick, Jeffrey C. Goh, & Richard H. De Boer. (2016). Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia-Pacific Journal of Clinical Oncology. 13(4). 266–276.
3.
Knox, Jennifer J., Carlos H. Barrios, Tae Min Kim, et al.. (2015). Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. Journal of Clinical Oncology. 33(15_suppl). 4554–4554.
4.
Klotz, Laurence, Matthew R. Smith, Robert E. Coleman, et al.. (2014). Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a phase III trial of denosumab for the prevention of skeletal-related events.. Journal of Clinical Oncology. 32(15_suppl). 5075–5075.
5.
Smith, Mitchell R., Robert E. Coleman, Laurence Klotz, et al.. (2014). Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology. 26(2). 368–374.
6.
Smith, Matthew R., Robert E. Coleman, Laurence Klotz, et al.. (2014). Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.. Journal of Clinical Oncology. 32(4_suppl). 35–35.
7.
Motzer, Robert J., Carlos H. Barrios, Tae Min Kim, et al.. (2013). Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 31(15_suppl). 4504–4504.
8.
Hutson, Thomas E., Bernard Escudier, E. Barrado, et al.. (2012). Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial. Annals of Oncology. 23. ixe14–ixe14.
9.
Singhal, Nimit, et al.. (2012). Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): COVeRT study.. Journal of Clinical Oncology. 30(15_suppl). e17544–e17544.
10.
Pittman, K., Amanda Townsend, Jennifer E. Hardingham, et al.. (2011). Small Cell Lung Cancer: Patterns of care and their influence on survival – 25 years experience of a single Australian oncology unit. Asia-Pacific Journal of Clinical Oncology. 7(3). 252–257.
11.
Pittman, K., Michael P. Brown, Bogda Koczwara, et al.. (2011). Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: Analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study. Journal of Geriatric Oncology. 2(4). 233–238.
12.
Stephenson, Sally‐Anne, et al.. (2009). Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. Journal of Hematology & Oncology. 2(1). 24–24.
13.
Price, Timothy, K. Pittman, W. K. Patterson, et al.. (2008). Management and Survival Trends in Advanced Colorectal Cancer. Clinical Oncology. 20(8). 626–630.
14.
Lüke, C., Bogda Koczwara, James Moore, et al.. (2005). Treatment and Survival from Colorectal Cancer: The Experience of Patients at South Australian Teaching Hospitals Between 1980 and 2002. Clinical Oncology. 17(5). 372–381.
15.
Joseph, David, D. Joshua, K. Pittman, et al.. (2004). Bisphosphonate infusions: patient preference, safety and clinic use. Supportive Care in Cancer. 12(6). 463–466.
16.
Price, Timothy, K. Pittman, Sung Hoon Sim, et al.. (2004). Survival and treatment trends for advanced colorectal cancer (CRC) treated in a University Hospital, 1992–2001. Journal of Clinical Oncology. 22(14_suppl). 3707–3707.
17.
Stephenson, Sally‐Anne, et al.. (2002). Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells. BMC Cancer. 2(1). 14–14.
18.
Pittman, K., et al.. (1996). Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Annals of Oncology. 7(3). 297–301.
19.
Pittman, K., Timothy Perren, John Primrose, et al.. (1993). Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Annals of Oncology. 4(6). 515–516.
20.
Smith, Brendan, Peter J. Selby, Jennifer Southgate, et al.. (1991). Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. The Lancet. 338(8777). 1227–1229.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Naoki Kanomata Breakdown of academic impact, for papers by Alison M. Schram Breakdown of academic impact, for papers by Shuchi S. Pandya Breakdown of academic impact, for papers by Lorenza Pecciarini Breakdown of academic impact, for papers by Yukishige Yamada Breakdown of academic impact, for papers by Sheryl K. Elkin Breakdown of academic impact, for papers by Laura Galluzzo Breakdown of academic impact, for papers by Pierre Rudolph Breakdown of academic impact, for papers by Patricia A. Shaw Breakdown of academic impact, for papers by Susanna Cappia